A Primer About Cannabidiol And The Benefits Of CBD


By Dr David Bearman

Scientists are rapidly discovering more and more about the rather amazing abilities of the cannabinoids found in the cannabis plant. Most of them have shown therapeutic value, as have the terpenes, which give the plant its distinct odors. There are over 125 terpenes and over 80 cannabinoids in cannabis and each strain has its own unique blend that create its distinct effects.

CBD is just one cannabinoid. Cannabinoids are 21-carbon molecules that block or stimulate endocannabinoid receptors. It’s known that other cannabinoids, such as THC, THCV, CBN and CBD, bind to CB1 and/or CB2 receptors, just as do the brain’s own naturally occurring cannabinoids – AEA and 2 AG.

Many of these cannabinoids have therapeutic value and CBD is no exception. It is a non-psychotropic cannabinoid, meaning it does not contribute to the euphoria associated with certain strains of cannabis. It is, however, psychoactive, because it crosses the blood-brain barrier. Unlike THC, CBD can be administered at relatively high doses without undesired psychological side effects.
Continue reading


Nature’s Miracle: Everything You Need to Know About CBD

Screen Shot 2019-01-17 at 11.46.57 PM.png

by Lisa Egan

Originally Published at Nutritional Anarchy

As more people seek natural remedies for health problems – and as more states legalize medical marijuana – interest in cannabidiol (commonly known as “CBD”) is growing.

It’s about time because CBD is a fascinating compound that has tremendous therapeutic value.
Continue reading

Cannabis: First-Line Not Last-Resort Medicine


By Susan Boskey

Who knew? In my article, Cannabis Kills Cancer Cells, I laid out the scientific evidence provided by in-vitro and lab animal testing. The fact of cannabis’ proven ability to kill cancer cells still only barely scratches the surface in terms of further needed assurances for the general public.
Continue reading

Banned Aid : Weed The World

A facebook group set up for conversations about how we manage cancer is inviting new members.
What began as a frustration with the shackled NHS has turned into a practical discussion about how the UK does, and might, manage cancer.

A very private Public figure, Dr Carol Coombes OBE recently came out about her own cancer, diagnosed in February 2017, to try to make changes to the current system in the UK that effectively gags NHS staff from discussing anything other than conventional radio and chemotherapy

Diagnosed in February 2017 with a ‘rare and aggressive’ tonsillar cancer, Carol immediately embarked on a series of lifestyle changes, aiming to rebuild her immune system. Her hope was that she could do this, and with regular monitoring and assessment from the NHS, be able to check on progress.

Continue reading

The Evolving Regulatory Status of Cannabidiol (Cannabis law is a lot wackier than the weed)

Read the full post at Project CBD

On June 25, 2018, the U.S. Food and Drug Administration (FDA) announced its first-ever approval of a marijuana-derived pharmaceutical drug. Epidiolex (cannabidiol or CBD) was approved for the treatment of two rare, pediatric seizure disorders, Lennox-Gastaut syndrome and Dravet syndrome.1 On September 27, 2018, the Drug Enforcement Administration (DEA) announced its scheduling of Epidiolex – and future drug products containing CBD derived from marijuana with no more than 0.1 percent tetrahydrocannabinols – in Schedule V of the Controlled Substances Act (CSA).2  These events represent historical milestones in the journey of Cannabis from a source of textiles and medicines in the early nineteenth century to an illicit drug and now an FDA-approved drug.

Cannabidiol (CBD) is one of more than a hundred cannabinoids found in Cannabis sativa L. (Cannabis spp. or Cannabis), a plant more well-known colloquially as “marijuana” or hemp [Please see Author’s Note below].3  CBD was first isolated in 1940 and characterized structurally in 1963.4,5 With projected retail sales of CBD products -hemp, marijuana and pharmaceutical – as high as $1.9 billion by 2020, CBD is poised to become the darling of the medical Cannabis movement.6

Convoluted law

Despite its rapidly growing popularity and use, the regulatory status of CBD in the United States remains convoluted, even after the approval and scheduling of Epidiolex. The source of CBD is critically important in determining its legal status. The most common source, botanically speaking, is the plant Cannabis sativa L. (Cannabis), which encompasses both marijuana and hemp. There are various schema for differentiating marijuana from hemp (e.g. Genotype, phenotype, Drug-type Cannabis v. fiber-type Cannabis, etc.), but from a regulatory standpoint, the difference between marijuana and hemp is based on chemical composition, specifically as it relates to the concentration of delta-9 Tetrahydrocannabinol (THC), the primary intoxicating compound found in Cannabis. Hemp is legally defined as a cultivar of Cannabis sativa with low concentrations of THC. Although limitations on THC concentrations for hemp differ internationally, THC concentrations cannot exceed three tenths of one percent (0.3%) in the United States. Hemp-derived and marijuana-derived CBD each have their own unique regulatory status and consequent legal implications.

Despite the scheduling of Epidiolex, CBD from marijuana is still deemed a Schedule I controlled substance by the DEA pursuant to the 1970 Controlled Substances Act. As such, CBD from marijuana is deemed to have no accepted medical use, a lack of accepted safety for use under medical supervision, and a high potential for abuse.1,7-11 While the scheduling of Epidiolex represents the first time that the DEA has acknowledged that marijuana has a “currently accepted medical use”, it did not change the regulatory status of CBD itself.

On May, 22, 2018, the DEA issued an internal directive which stated, “Products and materials that are made from the Cannabis plant and which fall outside the CSA definition of marijuana (such as sterilized seeds, oil or cake made from the seeds, and mature stalks) are not controlled under the CSA”.12 Although these statements clarified that CBD derived from a source other than marijuana was not a controlled substance, they did not specifically state that CBD from industrial hemp was lawful. Furthermore, these parts of the plant are not viable sources of CBD. As a result, confusion remains.

(Read the rest here)